Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study
-
Narrado por:
-
De:
Acerca de esta escucha
On this episode of the JVRD Author's Forum podcast, Dr. David Eichenbaum of Retina Vitreous Associates of Florida discusses "Biosimilar Ranibizumab (RaniEyes) Safety and Efficacy in the Real World: BRESER Study," published in the May/June 2025 issue of JVRD.
Host Dr. Timothy Murray and Dr. Eichenbaum talk about how biosimilars are developed and approved, and why real-world data is essential for evaluating their safety and effectiveness on a large scale. Learn why cost, access, and post-market surveillance are important factors in the growing role of biosimilars in retina care.
For more information, visit www.ASRS.org/JVRDForum.
Welcome to ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum. JVRD is the official scientific peer-reviewed journal of the American Society of Retina Specialists (ASRS), offering the highest quality and most impactful research and clinical information in the field. Join host Dr. Timothy Murray, Editor-in-Chief of JVRD, as he discusses cutting-edge developments featured in JVRD with the lead authors, who share clinical pearls and explore their significance in advancing patient care.